Patheos

BuddhistCatholicContemplativeEvangelicalGeneral ChristianHinduJewishLatter-day SaintMuslimNew VisionsProgressive Christian

Beliefs

Topics

Columnists

Resource Library

Research Tools

Video

Podcasts

Thought Readers

Faith In Media Tracker

Newsletters

Ad-Free & Subscriber Log-In Subscription Support

Patheos

Ad-Free & Subscriber Log-In Subscription Support

Follow Patheos Patheos on Facebook Patheos on YouTube

gospelforasia

Gospel for Asia: Detection and Vaccines Key in the Fight Against Leprosy (Part 1)

Last updated on: April 28, 2021 at 3:50 am   by GFA Staff Writer

Gospel for Asia: Detection and Vaccines Key in the Fight Against Leprosy (Part 1) 2021-04-28T03:50:29+00:00 GFA Staff Writer

LOGO Patheos Explore the world's faith through different perspectives on religion and spirituality! Patheos has the views of the prevalent religions and spiritualities of the world.

WILLS POINT, TX – Gospel for Asia (GFA World) founded by Dr. K.P. Yohannan issues the first part of a Special Report update on the current progress in the fight against leprosy where global leprosy-elimination leaders are making exciting advances both medically and socially.

Gospel for Asia (GFA) founded by Dr. K.P. Yohannan issues a Special Report update on the current progress in the fight against leprosy where global leprosy-elimination leaders are making exciting advances both medically and socially.

In 2018, another 208,619 new cases of leprosy were detected globally. Is any progress being made in the fight to eliminate leprosy?

In short, yes. Even detecting those new cases is one step closer to conquering leprosy. However, the fact that more than 200,000 people were diagnosed with leprosy reveals we still have work to do.

As discussed in Gospel for Asia’s previous Special Report, Leprosy: Misunderstandings and Stigma Keep it Alive, the fight against leprosy, also known as Hansen’s disease, has two main battlefronts. The first and most obvious is in the medical field: detecting and treating leprosy patients before they suffer permanent damage or transmit the disease to anyone else. The second battle line is equally important—and equally challenging: eliminating discrimination and stigma toward those affected by leprosy.

Global leprosy-elimination leaders are making exciting advances both medically and socially that are worth noting.

Gospel for Asia (GFA World) founded by Dr. K.P. Yohannan: Sabita is a cured leprosy patient.

Sabita is a cured leprosy patient who does not presently suffer from her sickness. She is able to walk to couple of kilometers a day, and do basic tasks like making tea. Although leprosy caused deformation in Sabita’s hands and body, it is completely cured now and she is experiencing life as a happy and content individual.

Medical Advances: Leprosy Prevention Is Key to Elimination

One of the great hindrances in eliminating leprosy is detecting and treating new cases before the infection spreads to others. Leprosy can take as long as 20 years to manifest physical signs of the infection and can spread to many vulnerable people during that incubation period. Additionally, because people with leprosy are frequently ostracized by society, many who suspect they have contracted leprosy will hide their condition, enabling transmission and going without the treatment that would save them from disfigurement.

Leprosy can take as long as 20 years
to manifest physical signs of the infection.

Multi-drug therapy (MDT) treatment has successfully cured leprosy patients since the 1980s, but it is not preventative in nature. The treatment does eliminate any chance of transmission in cured patients, but that alone cannot eliminate global leprosy due to the number of people who hide their condition. MDT also does not reverse any damage caused by the disease, so impacted nerves or wounds experienced from nerve damage remain as evidence of the patient’s traumatic health issue. Treatment must be provided prior to disfigurement in order to avoid these physical effects of leprosy.

For these reasons, preventing and quickly detecting new cases are vital partners to the established MDT treatment.

Photomicrograph of a skin tissue sample from a patient with leprosy reveals a cutaneous nerve invaded by numerous Mycobacterium leprae bacteria. Photo by Arthur E. Kaye, CDC

Photomicrograph of a skin tissue sample from a patient with leprosy reveals a cutaneous nerve invaded by numerous Mycobacterium leprae bacteria. Photo by Arthur E. Kaye, CDC

A Vaccine for Leprosy

A new player for leprosy elimination is on the horizon: a leprosy vaccine. American Leprosy Missions (ALM), a Christian organization focusing on aiding those impacted by neglected tropical diseases, is 17 years into its partnership with the Infectious Disease Research Institute to develop the world’s first leprosy-specific vaccine. The vaccine, LepVax, has proven hopeful during the development process and is currently being tested among volunteers in a leprosy-endemic area.

In its recent report on the Phase 1a clinical trial, ALM writes, “We believe this leprosy vaccine will be an exciting new way to stop the transmission of leprosy and the only way to protect people long term. What’s more, the vaccine may protect against nerve damage among those already diagnosed with leprosy, the most serious complication of leprosy.”

If people living in areas with high rates of leprosy received a leprosy vaccine, new cases could be avoided—an incredible landmark in global leprosy elimination. This promising vaccine is projected to be in Phase 1b clinical trials for another two years before moving on in the development process.

Preventative Medication

Another exciting new shift in the world of leprosy is the use of preventative medication for those at risk of developing leprosy. This relatively new practice takes one of the drugs used in the MDT treatment, rifampicin, and administers it to people in frequent proximity to those with leprosy, such as family members of leprosy patients or those living in endemic areas.

ALM provided 7,091 pounds of critical medicines and supplies to Ghana partners. Photo by ALM

ALM provided 7,091 pounds of critical medicines and supplies to Ghana partners. Photo by ALM

This single-dose rifampicin (SDR) treatment reduces people’s risk of developing leprosy by 60 percent, whether or not they have previously been exposed to the disease. It is not a magic cure—success rates vary among the different kinds of leprosy, and protection only lasts a few years—but it has an additional benefit. Providing this treatment for those at risk of contracting leprosy also enables medical workers to discover early cases of leprosy in people who might otherwise not be examined. The stigma around leprosy, however, has barred the way for medical treatment in many areas. Many people still hesitate to do anything in connection to leprosy treatment, even if it is preventative.

Resources to overcome challenges like this were presented during the 20th International Leprosy Congress. In September 2019, more than 1,000 people from 55 countries gathered in Manila, Philippines, for the Congress. There, scientists, practitioners and leprosy advocates shared research, ideas and resources to further their goal of zero leprosy.

During the Congress, the Global Partnership for Zero Leprosy launched the Best Practices Zero Leprosy Toolkit, designed to “support countries in their work towards ending leprosy and its associated disabilities and stigma.”

Just one of the valuable resources this kit contains is advice on how to prepare communities to be favorable toward receiving preventative SDR.

Medical personnel found that performing pre-treatment counselling in communities promoted willingness toward participation in the SDR preventative treatment. Education about leprosy made 90 percent of those in close connection to leprosy patients willing to participate in the treatment.


Progress in the Fight Against Leprosy — Leprosy Prevention is Key to Elimination: Part 2

This Special Report originally appeared on gfa.org.

Read another Special Report from Gospel for Asia on Leprosy: Misunderstandings.


Learn more about the GFA-supported leprosy ministry, or the Reaching Friends Ministry, helping remind people affected by leprosy that, despite the stigma of leprosy, they have dignity and are valued by God.

Click here, to read more blogs on Patheos from Gospel for Asia.

Learn more about Gospel for Asia: Facebook | YouTube | Instagram | LinkedIn | SourceWatch | Integrity | Lawsuit Update | 5 Distinctives | 6 Remarkable Facts | 10 Milestones | Media Room | Poverty Alleviation | Endorsements | 40th Anniversary | Lawsuit Response |

Notable news about Gospel for Asia: FoxNews, ChristianPost, NYPost, MissionsBox

Humanitarian Services

Leprosy

Medical Ministry

National Missions

Special Report

Define Leprosy

Gospel for Asia

Images of Leprosy

Is Leprosy Contagious

Is Leprosy Curable

Leprosy

Leprosy Cure

Leprosy Images

Leprosy Photos

Leprosy Pics

Leprosy Pictures

Leprosy Stigma

Leprosy Symptoms

Leprosy Treatment

Photos of Lepers

Pics of Lepers

Pics of Leprosy

Pictures of Leprosy

What Causes Leprosy

What Does Leprosy Look Like

What is Leprosy

Previous Post



March 13, 2020

Gospel for Asia Tells of Happiness and a Hand Tricycle

Next Post



March 15, 2020 Gospel for Asia: Fight for Zero Leprosy a Critical Human Rights Issue (Part 2)


Browse Our Archives

Select a Category About Gospel for Asia Bishop Daniel Children's Education Clean Water Daniel Yohannan Disaster Relief GFA World Guest Writer Humanitarian Services Inspiration Leprosy Medical Ministry Mission Support Team Modern Slavery National Missions Poverty Alleviation Powerful Prayer School of Discipleship Special Report Spiritual Growth Uncategorized Women's Issues

Select a Month April 2026 March 2026 December 2025 September 2025 June 2025 May 2025 March 2025 December 2024 November 2024 October 2024 June 2024 May 2024 April 2024 December 2023 November 2023 October 2023 September 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 November 2021 October 2021 September 2021 August 2021 July 2021 June 2021 May 2021 April 2021 March 2021 February 2021 December 2020 November 2020 October 2020 September 2020 August 2020 July 2020 June 2020 May 2020 April 2020 March 2020 February 2020 January 2020 December 2019 November 2019 October 2019 September 2019 August 2019 July 2019 June 2019 May 2019 April 2019 March 2019 February 2019 January 2019 December 2018 November 2018 October 2018 September 2018 August 2018 July 2018 June 2018 May 2018 April 2018 March 2018 February 2018 January 2018 December 2017 November 2017 October 2017 September 2017


Follow Us!

Follow Us on Facebook Follow Us on Twitter



TAKE THE

Religious Wisdom Quiz

Who said, "Lord, to whom shall we go? You have the words of eternal life"?

Select your answer to see how you score.

John Peter James Paul

Related posts from What Motivates Us.

Family

GFA World ‘Epicenter’ for Faith-Based Healthcare in Africa

What Motivates Us.

Family

GFA World Extends Missionary Movement to Liberia, Africa

What Motivates Us.

Family

Christmas Chicken Challenge Helps Families Fly Poverty Coop

What Motivates Us.

Family

GFA World & Ministry Leaders Celebrate KP Yohannan...

What Motivates Us.

TRENDING AT PATHEOS Evangelical

Advice to Democrats

Lots of people are offering advice to the Democratic Party and its...

Sunday Readings: Using God’s Gifts Faithfully

The readings for the Thirty-Third Sunday in Ordinary Time remind us to...

Donald Trump's Heaven? No Room For God

Donald Trump’s heaven would be filled with grudges, backbiting, refusal both to...

Peruvian airplane ready for Pope Leo XIV

The Chilean airline LATAM which serves as the main domestic flight provider...

Bear One Another’s Burdens, But Carry Your Own...

At first glance, Paul seems to contradict himself within the span of...

A Catholic Century or an Evangelical Century?

Will the form of Christianity that prevails in the years ahead be...

view all Evangelical blogs

Patheos on Facebook Patheos on YouTube

Ad-Free & Subscriber Log-In Subscription Support

Copyright 2008-2026, Patheos. All rights reserved.

Subscription Support Ad-Free & Subscriber Log-In

Follow Patheos Patheos on Facebook Patheos on YouTube